Abpro Holdings, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jin Wook Suk
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 Summit Drive Burlington MA United States of America 01801
- IPO Date
- Mar 9, 2022
- CIK
- 0001893219
- Website
- abpro.co
- Similar Companies
- Business
- Abpro Holdings, Inc. engages in the development of next-generation antibody therapeutics with a focus on immuno-oncology and ophthalmology. It leverages its DiversImmune and MultiMab antibody discovery and engineering platforms to build a pipeline of antibody candidates for independent development and in collaboration with global pharmaceutical and research institutions. Core product candidates include ABP-102, a next-generation immuno-oncology antibody targeting HER2 and CD3 for HER2-positive solid tumors such as breast and gastric cancers, and ABP-201, a TetraBi antibody format that co-inhibits VEGF and ANG-2 for vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. The company pursues partnerships to advance clinical programs and expand its scientific platform capabilities. Abpro Holdings, Inc. operates primarily in the United States with headquarters in Woburn, Massachusetts, and maintains a focus on strategic collaborations and licensing arrangements to extend its therapeutic pipeline, while exploring additional indications across oncology and ophthalmology. The firm was founded in 2004 and previously operated under the name Abpro Corporation until rebranding to Abpro Holdings, Inc. in 2024, reflecting its evolving corporate structure and growth strategy. The company’s activities span discovery, engineering, preclinical research, and early-stage clinical development, supported by research partnerships and potential contract manufacturing arrangements as it monetizes its antibody platforms and candidate products. Abpro Holdings, Inc. maintains an emphasis on translating antibody innovation into targeted therapies for cancer and ocular vascular diseases, with geographic and strategic expansion guided by alliance opportunities and capital market developments. The company’s business model centers on platform-driven product development, collaboration-based value creation, and selective licensing or milestone-based earnings tied to partnered programs. Abpro Holdings, Inc. maintains regulatory and investor relations communications to delineate its strategic progress, pipeline advancement, and corporate actions.
Short Interest in Abpro Holdings Inc. (NASDAQ:ABP) Increases By 271.4%
Abpro's Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72
Abpro (NASDAQ:ABP) Stock Price Up 0.2% – Still a Buy?
Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers
Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives
Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager
Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025
Abpro Holdings Inc. (NASDAQ:ABP) Sees Large Decrease in Short Interest
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025
Abpro Statement on the Departure of Former CEO Ian Chan
Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing